Abstract
Objective. To compare the efficacy and tolerability of cyclosporine (CSA) with that of symptomatic therapy (ST) alone and sulfasalazine (SSZ) in the treatment of psoriatic arthritis (PsA). Methods. Twelve rheumatology centers recruited 99 patients with active PsA in a 24 week, prospective, randomized, open, controlled study. The patients were treated with CSA (3 mg/kg/day) or SSZ (2000 mg/day) plus ST, or ST alone (nonsteroidal antiinflammatory drugs, analgesics, and/or prednisone≤5 mg/day). The primary endpoint was the 6 month change in pain. Analyses were on the basis of the intention-to-treat principle. Results. In comparison with both SSZ and ST, there was a statistically significant difference in favor of CSA in terms of the mean changes in the pain score (p
Original language | English |
---|---|
Pages (from-to) | 2274-2282 |
Number of pages | 9 |
Journal | Journal of Rheumatology |
Volume | 28 |
Issue number | 10 |
Publication status | Published - 2001 |
Keywords
- Low dose cyclosporine
- Psoriatic arthritis
- Sulfasalazine
- Symptomatic therapy
ASJC Scopus subject areas
- Rheumatology
- Immunology